Desvenlafaxine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder. The primary active metabolite of venlafaxine, administered as its succinate salt. Offers more predictable pharmacokinetics than venlafaxine since it does not require CYP2D6 metabolism for activation, reducing variability among patients with different CYP2D6 genotypes. Dosage must be determined by your prescribing physician.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder. NutriStack rates the supporting evidence as strong. Common adult dosing is 50 mg daily (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete sodium. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: depression symptom relief, predictable pharmacokinetics, minimal cyp2d6-dependent metabolism. 10 sources indexed (2015–2023), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Inhibits the reuptake of both serotonin (5-HT) and norepinephrine (NE) by blocking SERT and NET. As the active metabolite of venlafaxine, it provides direct dual reuptake inhibition without requiring hepatic activation.
Dosing & protocol.
Can be taken with or without food. Swallow whole; do not crush, chew, or dissolve. Taper gradually when discontinuing.
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Sodium
ModerateAntidepressant-associated SIADH can increase renal free-water retention and dilute serum sodium, producing hyponatremia.
Full safety detail.
Side effects
- Nausea
- Dizziness
- Insomnia
- Hyperhidrosis
- Constipation
- Decreased appetite
- Sexual dysfunction
- Elevated blood pressure
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
1- 1Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysisPMIDLaoutidis ZG, Kioulos KT · Pharmacopsychiatry · 2015
Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry. 2015
Randomized controlled trials
6- 2A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorderPMIDZhao Q, Fu B, Lyu N et al. · Journal of affective disorders · 2023
Zhao Q, Fu B, Lyu N et al.. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. Journal of affective disorders. 2023
- 3A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorderPMIDBansal R, Hellerstein DJ, Sawardekar S et al. · Psychiatry research. Neuroimaging · 2023
Bansal R, Hellerstein DJ, Sawardekar S et al.. A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder. Psychiatry research. Neuroimaging. 2023
- 4Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysisPMIDKatzman MA, Wang X, Wajsbrot DB et al. · Journal of psychopharmacology (Oxford, England) · 2020
Katzman MA, Wang X, Wajsbrot DB et al.. Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. Journal of psychopharmacology (Oxford, England). 2020
- 5Desvenlafaxine vs. placebo in the treatment of persistent depressive disorderPMIDHellerstein DJ, Stewart JW, Chen Y et al. · Journal of affective disorders · 2019
Hellerstein DJ, Stewart JW, Chen Y et al.. Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder. Journal of affective disorders. 2019
- 6Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive DisorderPMIDAtkinson S, Lubaczewski S, Ramaker S et al. · Journal of child and adolescent psychopharmacology · 2018
Atkinson S, Lubaczewski S, Ramaker S et al.. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. Journal of child and adolescent psychopharmacology. 2018
- 7Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive DisorderPMIDWeihs KL, Murphy W, Abbas R et al. · Journal of child and adolescent psychopharmacology · 2018
Weihs KL, Murphy W, Abbas R et al.. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder. Journal of child and adolescent psychopharmacology. 2018
Reference material
3- 8Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018.Source linkedPMID
- 9Thase ME et al. Efficacy of desvenlafaxine 50 mg and 100 mg in adults with major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017.Source linkedPMID
- 10Gomez-Lumbreras A et al. Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta-analysis. Br J Clin Pharmacol. 2026.Source linkedPMID
Common questions.
Quick answers about Desvenlafaxine, drawn from the data on this page.
What is Desvenlafaxine?
Prescription serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder. The primary active metabolite of venlafaxine, administered as its succinate salt. Offers more predictable pharmacokinetics than venlafaxine since it does not require CYP2D6 metabolism for activation, reducing variability among patients with different CYP2D6 genotypes. Dosage must be determined by your prescribing physician.
What is Desvenlafaxine used for?
Commonly cited benefits of Desvenlafaxine include: Depression symptom relief; Predictable pharmacokinetics; Minimal CYP2D6-dependent metabolism; Anxiety symptom improvement. NutriStack rates the overall evidence as strong.
What is a typical dose of Desvenlafaxine?
A typical adult dose of Desvenlafaxine is 50 mg daily (as prescribed by your physician). The commonly recommended form is Extended-release tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Desvenlafaxine?
Reported side effects include nausea, dizziness, insomnia, hyperhidrosis, constipation, decreased appetite. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Desvenlafaxine?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Desvenlafaxine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.